Cited by CrossRef (6)
- Rasa Islam, Aleta Pupovac, Vera Evtimov, Nicholas Boyd, Runzhe Shu, Richard Boyd, Alan Trounson. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. Cells 2021;10:1058

- Ahmet ACAR. Integrative profiling of CEACAM1 in different malignancies with implications on the SARS-CoV-2 infection genes ACE2 and TMPRSS2. 2023;51:215

- Alessandro Poggi, Maria Raffaella Zocchi. Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Molecular Therapy - Oncolytics 2022;24:26

- Ashraf Abdullah Saad. Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life 2022;15:378

- Nina Miazek-Zapala, Aleksander Slusarczyk, Aleksandra Kusowska, Piotr Zapala, Matylda Kubacz, Magdalena Winiarska, Malgorzata Bobrowicz. The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 2021;10:1511

- Alaa M. Khalifa, Takashi Nakamura, Yusuke Sato, Takanori Sato, Mamoru Hyodo, Yoshihiro Hayakawa, Hideyoshi Harashima. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. International Journal of Pharmaceutics 2022;624:122034
